|
US4873192A
(en)
|
1987-02-17 |
1989-10-10 |
The United States Of America As Represented By The Department Of Health And Human Services |
Process for site specific mutagenesis without phenotypic selection
|
|
NZ227684A
(en)
|
1988-01-30 |
1991-07-26 |
Merck Sharp & Dohme |
Pyrazine, pyridazine, and pyrimidine derivatives and pharmaceutical compositions
|
|
GB9005737D0
(en)
|
1990-03-14 |
1990-05-09 |
Beecham Group Plc |
Novel compounds
|
|
FR2676444B1
(fr)
*
|
1991-05-16 |
1995-03-10 |
Sanofi Elf |
Nouveaux derives d'amino-3 pyridazines actifs sur le systeme nerveux central, procede de preparation et compositions pharmaceutiques en contenant.
|
|
EP1191097A1
(en)
|
2000-09-21 |
2002-03-27 |
Leids Universitair Medisch Centrum |
Induction of exon skipping in eukaryotic cells
|
|
CA2457527A1
(en)
|
2001-08-31 |
2003-03-13 |
Gen-Probe Incorporated |
Affinity-shifted probes for quantifying analyte polynucleotides
|
|
US7135484B2
(en)
|
2002-08-14 |
2006-11-14 |
Abbott Laboratories |
Azabicyclic compounds are central nervous system active agents
|
|
NZ538512A
(en)
|
2002-09-30 |
2006-12-22 |
Neurosearch As |
1,4-diazabicycloalkane derivatives, their preparation and use in treatment of disorders responsive to modulation of cholmergic and/or monoamine receptors
|
|
US8014953B2
(en)
|
2003-08-08 |
2011-09-06 |
The Regents Of The University Of California |
RNA surveillance among curated proteins
|
|
US7399765B2
(en)
|
2003-09-19 |
2008-07-15 |
Abbott Laboratories |
Substituted diazabicycloalkane derivatives
|
|
US7160876B2
(en)
|
2003-12-22 |
2007-01-09 |
Abbott Laboratories |
Fused bicycloheterocycle substituted quinuclidine derivatives
|
|
US7309699B2
(en)
|
2003-12-22 |
2007-12-18 |
Abbott Laboratories |
3-Quinuclidinyl amino-substituted biaryl derivatives
|
|
US7655657B2
(en)
|
2003-12-22 |
2010-02-02 |
Abbott Laboratories |
Fused bicycloheterocycle substituted quinuclidine derivatives
|
|
US7309487B2
(en)
|
2004-02-09 |
2007-12-18 |
George Inana |
Methods and compositions for detecting and treating retinal diseases
|
|
AR049401A1
(es)
|
2004-06-18 |
2006-07-26 |
Novartis Ag |
Aza-biciclononanos
|
|
GB0415746D0
(en)
|
2004-07-14 |
2004-08-18 |
Novartis Ag |
Organic compounds
|
|
ATE520692T1
(de)
|
2004-10-07 |
2011-09-15 |
Merck Sharp & Dohme |
Thiazolyl-mglur5-antagonisten und verfahren zu ihrer verwendung
|
|
CA2583217C
(en)
|
2004-10-18 |
2011-05-31 |
Amgen Inc. |
1,3,4-thiadiazole compounds as protein kinase inhibitors
|
|
US7838657B2
(en)
|
2004-12-03 |
2010-11-23 |
University Of Massachusetts |
Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences
|
|
MX2007009017A
(es)
|
2005-01-26 |
2007-09-19 |
Schering Corp |
Derivados de 3-(indazol-5-il)-(1,2,4)triazina y compuestos relacionados como inhibidores de proteina cinasa para el tratamiento de cancer.
|
|
WO2006113704A2
(en)
|
2005-04-18 |
2006-10-26 |
Neurogen Corporation |
Subtituted heteroaryl cb1 antagonists
|
|
US7598052B2
(en)
|
2005-10-11 |
2009-10-06 |
The Regents Of The University Of Michigan |
Expression profile of thyroid cancer
|
|
US8603457B2
(en)
|
2005-12-02 |
2013-12-10 |
University Of Rochester |
Nonsense suppression and genetic codon alteration by targeted modification
|
|
US7834178B2
(en)
|
2006-03-01 |
2010-11-16 |
Bristol-Myers Squibb Company |
Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
|
|
NZ589784A
(en)
*
|
2006-05-19 |
2012-05-25 |
Abbott Lab |
Cns active fused bicycloheterocycle substituted azabicyclic alkane derivatives
|
|
JP5290964B2
(ja)
|
2006-05-30 |
2013-09-18 |
ノイロサーチ アクティーゼルスカブ |
新規１，４−ジアザ−ビシクロ［３．２．２］ノニルオキサジアゾリル誘導体及びそれらの医学的使用
|
|
US8314119B2
(en)
|
2006-11-06 |
2012-11-20 |
Abbvie Inc. |
Azaadamantane derivatives and methods of use
|
|
US8343941B2
(en)
|
2007-03-30 |
2013-01-01 |
Rutgers, The State University Of New Jersey |
Compositions and methods for gene silencing
|
|
US8283116B1
(en)
|
2007-06-22 |
2012-10-09 |
Ptc Therapeutics, Inc. |
Methods of screening for compounds for treating spinal muscular atrophy using SMN mRNA translation regulation
|
|
DE102007032507A1
(de)
*
|
2007-07-12 |
2009-04-02 |
Merck Patent Gmbh |
Pyridazinonderivate
|
|
ES2914775T3
(es)
|
2007-10-26 |
2022-06-16 |
Academisch Ziekenhuis Leiden |
Medios y métodos para contrarresta trastornos del músculo
|
|
MX2010005648A
(es)
|
2007-11-21 |
2010-06-02 |
Abbott Lab |
Derivados de alcano azabiciclico sustituidos con biarilo como moduladores de la actividad del receptor nicotinico de acetilcolina.
|
|
US8437067B2
(en)
|
2008-03-18 |
2013-05-07 |
Konica Minolta Holdings, Inc. |
Electrochemical display element
|
|
WO2009151546A2
(en)
|
2008-05-27 |
2009-12-17 |
Ptc Therapeutics, Inc. |
Methods for treating spinal muscular atrophy
|
|
US8133724B2
(en)
|
2008-09-17 |
2012-03-13 |
University Of Maryland, Baltimore |
Human androgen receptor alternative splice variants as biomarkers and therapeutic targets
|
|
RU2505540C2
(ru)
|
2008-12-23 |
2014-01-27 |
Эббви Инк. |
Антивирусные соединения
|
|
WO2010107733A2
(en)
|
2009-03-16 |
2010-09-23 |
Curna, Inc. |
Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2
|
|
DK2417257T3
(da)
|
2009-04-10 |
2016-06-06 |
Ass Inst De Myologie |
Tricyclo-dna-antisense-oligonukleotider, sammensætninger, og fremgangsmåder til behandlingen af sygdom
|
|
SMT202000020T1
(it)
|
2009-06-17 |
2020-03-13 |
Biogen Ma Inc |
Composizioni e metodi per la modulazione di splicing di smn2 in un soggetto
|
|
TWI558398B
(zh)
|
2009-09-22 |
2016-11-21 |
諾華公司 |
菸鹼乙醯膽鹼受體α７活化劑之用途
|
|
EP2305679A1
(en)
|
2009-09-28 |
2011-04-06 |
GenKyoTex SA |
Pyrazoline dione derivatives as nadph oxidase inhibitors
|
|
TW201129361A
(en)
*
|
2010-01-20 |
2011-09-01 |
Abbott Lab |
Methods for treating pain
|
|
RU2625791C2
(ru)
|
2010-02-05 |
2017-07-19 |
Хептейрес Терапьютикс Лимитед |
Производные 1,2,4-триазин-4-амина
|
|
AR081626A1
(es)
|
2010-04-23 |
2012-10-10 |
Cytokinetics Inc |
Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
|
|
WO2011133920A1
(en)
|
2010-04-23 |
2011-10-27 |
Cytokinetics, Inc. |
Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
|
|
AR081331A1
(es)
|
2010-04-23 |
2012-08-08 |
Cytokinetics Inc |
Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
|
|
US8802642B2
(en)
|
2010-04-28 |
2014-08-12 |
Iowa State University Research Foundation, Inc. |
Spinal muscular atrophy treatment via targeting SMN2 catalytic core
|
|
WO2011163636A2
(en)
|
2010-06-24 |
2011-12-29 |
The Regents Of The University Of California |
Compounds and uses thereof in modulating levels of various amyloid beta peptide alloforms
|
|
US8791136B2
(en)
|
2010-07-29 |
2014-07-29 |
Rigel Pharmaceuticals, Inc. |
Substituted pyridine, pyridazine, pyrazine and pyrimidine compounds and methods for using the same
|
|
CN103732258A
(zh)
|
2011-03-14 |
2014-04-16 |
Nse产品公司 |
用于促进细胞纯化的口服制剂
|
|
WO2012129562A2
(en)
|
2011-03-24 |
2012-09-27 |
The Scripps Research Institute |
Compounds and methods for inducing chondrogenesis
|
|
WO2013019938A1
(en)
|
2011-08-02 |
2013-02-07 |
The Brigham And Women's Hospital, Inc. |
Pyridazine derivatives as eaat2 activators
|
|
EP2771069A4
(en)
|
2011-10-27 |
2015-08-26 |
Mayo Foundation |
INHIBITION OF G-PROTEIN-COUPLED RECEPTOR-6-KINASE POLYPEPTIDE
|
|
CN104244944B
(zh)
|
2011-12-30 |
2018-06-08 |
Ptc医疗公司 |
用于治疗脊髓性肌萎缩症的化合物
|
|
EP2809322B9
(en)
|
2012-01-26 |
2019-10-30 |
PTC Therapeutics, Inc. |
Compounds for treating spinal muscular atrophy
|
|
MX354074B
(es)
|
2012-02-10 |
2018-02-12 |
Ptc Therapeutics Inc |
Compuestos para tratar la atrofia muscular espinal.
|
|
WO2013117693A1
(en)
|
2012-02-10 |
2013-08-15 |
Glaxosmithkline Intellectual Property Development Limited |
Pde4 inhibitor for treating huntington's disease
|
|
JP6092264B2
(ja)
|
2012-03-01 |
2017-03-08 |
ピーティーシー セラピューティクス， インコーポレイテッド |
脊髄性筋委縮症を処置するための化合物
|
|
CN104470909B
(zh)
|
2012-03-23 |
2018-04-24 |
Ptc医疗公司 |
用于治疗脊髓性肌萎缩的化合物
|
|
US8729263B2
(en)
*
|
2012-08-13 |
2014-05-20 |
Novartis Ag |
1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
|
|
AU2013204200B2
(en)
|
2012-10-11 |
2016-10-20 |
Brandeis University |
Treatment of amyotrophic lateral sclerosis
|
|
FI2906696T4
(fi)
|
2012-10-15 |
2023-03-18 |
|
Menetelmiä c9orf72:n ilmentymisen moduloimiseksi
|
|
CN105246485B
(zh)
*
|
2013-01-15 |
2019-03-15 |
诺华有限公司 |
α7烟碱型乙酰胆碱受体激动剂的应用
|
|
ES2883232T3
(es)
*
|
2013-01-15 |
2021-12-07 |
Novartis Ag |
Uso de agonistas del receptor nicotínico de acetilcolina alfa 7
|
|
ES2701083T3
(es)
*
|
2013-01-15 |
2019-02-20 |
Novartis Ag |
Uso de agonistas del receptor nicotínico alfa 7 para el tratamiento de la narcolepsia
|
|
ITMI20130063A1
(it)
*
|
2013-01-17 |
2014-07-18 |
Valier Alberto |
Dispositivo manuale per la raccolta dal suolo di frutti o altri oggetti
|
|
US9040712B2
(en)
|
2013-01-23 |
2015-05-26 |
Novartis Ag |
Thiadiazole analogs thereof and methods for treating SMN-deficiency-related-conditions
|
|
KR102314290B1
(ko)
|
2013-06-25 |
2021-10-21 |
에프. 호프만-라 로슈 아게 |
척수성 근위축증을 치료하기 위한 화합물
|
|
AU2014296255B2
(en)
|
2013-07-31 |
2017-08-03 |
Novartis Ag |
1,4-disubstituted pyridazine derivatives and their use for treating SMN-deficiency-related conditions
|
|
JP6689197B2
(ja)
|
2013-08-19 |
2020-04-28 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
スクリーニング方法
|
|
EP3039019B1
(en)
|
2013-08-26 |
2020-04-22 |
Purdue Pharma L.P. |
Azaspiro[4.5]decane derivatives and use thereof
|
|
EP3052654A4
(en)
|
2013-09-30 |
2017-05-03 |
The Regents of the University of California |
Identification of structurally similar small molecules that enhance therapeutic exon skipping
|
|
US11162096B2
(en)
|
2013-10-14 |
2021-11-02 |
Ionis Pharmaceuticals, Inc |
Methods for modulating expression of C9ORF72 antisense transcript
|
|
WO2015136947A1
(en)
|
2014-03-14 |
2015-09-17 |
Raqualia Pharma Inc. |
Azaspiro derivatives as trpm8 antagonists
|
|
US10006027B2
(en)
|
2014-03-19 |
2018-06-26 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating Ataxin 2 expression
|
|
US10724092B2
(en)
|
2014-06-10 |
2020-07-28 |
Erasmus University Medical Center Rotterdam |
Methods for characterizing alternatively or aberrantly spliced mRNA isoforms
|
|
GB201410693D0
(en)
|
2014-06-16 |
2014-07-30 |
Univ Southampton |
Splicing modulation
|
|
WO2016037039A1
(en)
|
2014-09-04 |
2016-03-10 |
Rutgers, The State University Of New Jersey |
Compositions for increasing survival of motor neuron protein (smn) levels in target cells and methods of use thereof for the treatment of spinal muscular atrophy
|
|
US20170334977A1
(en)
|
2014-10-20 |
2017-11-23 |
The Brigham And Women's Hospital, Inc. |
Targeting Apolipoprotein E (APOE) in Neurologic Disease
|
|
US10053697B1
(en)
|
2015-01-09 |
2018-08-21 |
The Board Of Trustees Of The Leland Stanford Junior University |
Programmable alternative splicing devices and uses thereof
|
|
EP3247701B1
(en)
|
2015-01-20 |
2021-09-22 |
Boehringer Ingelheim Animal Health USA Inc. |
Anthelmintic compounds, compositions and method of using thereof
|
|
JP6884102B2
(ja)
|
2015-02-09 |
2021-06-09 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
がんの治療のための化合物
|
|
EP3053577A1
(en)
|
2015-02-09 |
2016-08-10 |
F. Hoffmann-La Roche AG |
Compounds for the treatment of cancer
|
|
EP4249472A3
(en)
*
|
2015-05-30 |
2023-12-13 |
PTC Therapeutics, Inc. |
Methods for modulating rna splicing
|
|
IL305843B2
(en)
|
2015-07-20 |
2025-01-01 |
Genzyme Corp |
CSF-1R receptor antibodies
|
|
WO2017041036A1
(en)
|
2015-09-02 |
2017-03-09 |
Pathways Bioscience, Llc |
Compositions and methods for treatment or prevention of oral mucositis
|
|
CA2998826A1
(en)
|
2015-09-24 |
2017-03-30 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Modulators of indoleamine 2,3-dioxygenase
|
|
WO2017062751A1
(en)
|
2015-10-08 |
2017-04-13 |
The Regents Of The University Of California |
Compounds and methods for promoting stress resistance
|
|
KR20220105174A
(ko)
|
2015-10-09 |
2022-07-26 |
유니버시티 오브 사우스앰톤 |
유전자 발현의 조절 및 탈조절된 단백질 발현의 스크리닝
|
|
EP3183347A4
(en)
*
|
2015-10-17 |
2018-04-18 |
Lifesplice Pharma LLC |
Splice modulating oligonucleotides and methods of use thereof
|
|
EA036399B1
(ru)
|
2015-11-12 |
2020-11-06 |
Ф. Хоффманн-Ля Рош Аг |
Композиции для лечения спинальной мышечной атрофии
|
|
US20180344680A1
(en)
|
2015-12-08 |
2018-12-06 |
The Arizona Board Of Regents On Behalf Of The University Of Arizona |
Compositions and methods for treatment, amelioration, and prevention of diabetes-related skin ulcers
|
|
MX391850B
(es)
|
2015-12-10 |
2025-03-19 |
Ptc Therapeutics Inc |
Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington
|
|
US11096956B2
(en)
|
2015-12-14 |
2021-08-24 |
Stoke Therapeutics, Inc. |
Antisense oligomers and uses thereof
|
|
EP3405478A4
(en)
|
2015-12-23 |
2019-10-30 |
Moonshot Pharma LLC |
METHOD FOR INDUCING AN IMMUNE RESPONSE BY INHIBITING NONSENSE-MEDIATED CRASH
|
|
JP2019501979A
(ja)
|
2016-01-15 |
2019-01-24 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． |
Ｅａａｔ２活性化剤としてのピリダジン誘導体
|
|
RU2018127537A
(ru)
|
2016-02-01 |
2020-03-03 |
Арракис Терапьютикс, Инк. |
Соединения и способы лечения phk-опосредованных заболеваний
|
|
AU2017223706A1
(en)
|
2016-02-23 |
2018-09-20 |
Indiana University Research & Technology Corporation |
Combination therapies for treatment of spinal muscular atrophy
|
|
EP3423158B1
(en)
|
2016-02-24 |
2023-11-15 |
The Rockefeller University |
Embryonic cell-based therapeutic candidate screening systems, models for huntington's disease and uses thereof
|
|
US11066456B2
(en)
|
2016-02-25 |
2021-07-20 |
Washington University |
Compositions comprising TREM2 and methods of use thereof
|
|
US20170268066A1
(en)
|
2016-03-15 |
2017-09-21 |
Chalmers Ventures Ab |
Cancer biomarkers
|
|
ES2797301T3
(es)
|
2016-03-29 |
2020-12-01 |
Merck Patent Gmbh |
Derivados de piperidinil-propanona
|
|
EP3440100A4
(en)
|
2016-04-04 |
2020-01-22 |
University of Florida Research Foundation, Incorporated |
HANDLING EIF3 TO MODULATE A NON-ATG TRANSLATION ASSOCIATED WITH A REPETITION (RAN)
|
|
WO2017178510A1
(en)
|
2016-04-12 |
2017-10-19 |
Laboratorios Del Dr. Esteve, S.A. |
Arylamide derivatives having multimodal activity against pain
|
|
HUE051480T2
(hu)
|
2016-06-13 |
2021-03-01 |
Scholar Rock Inc |
Miosztatin-inhibitorok alkalmazása és kombinációs terápiák
|
|
EP3478842A4
(en)
*
|
2016-07-01 |
2020-04-15 |
Arrakis Therapeutics, Inc. |
COMPOUNDS AND METHODS FOR MODULATING RNA FUNCTION
|
|
MX2019005588A
(es)
|
2016-11-28 |
2019-10-15 |
Ptc Therapeutics Inc |
Metodos para modular corte y empalme de arn.
|
|
CN114432318A
(zh)
|
2017-02-20 |
2022-05-06 |
国立大学法人京都大学 |
用于起因于剪接异常的遗传性疾病的药物组合物及治疗方法
|
|
US11715549B2
(en)
|
2017-05-01 |
2023-08-01 |
Thomas Jefferson University |
Systems-level analysis of 32 TCGA cancers reveals disease-dependent tRNA fragmentation patterns and very selective associations with messenger RNAs and repeat elements
|
|
KR20200017476A
(ko)
|
2017-06-14 |
2020-02-18 |
피티씨 테라퓨틱스, 인크. |
Rna 스플라이싱의 변경 방법
|
|
US11382918B2
(en)
|
2017-06-28 |
2022-07-12 |
Ptc Therapeutics, Inc. |
Methods for treating Huntington's Disease
|
|
MX2019015580A
(es)
|
2017-06-28 |
2020-07-28 |
Ptc Therapeutics Inc |
Metodos para tratar la enfermedad de huntington.
|
|
MY201938A
(en)
|
2017-08-04 |
2024-03-25 |
Skyhawk Therapeutics Inc |
Methods and compositions for modulating splicing
|
|
CN109843872B
(zh)
|
2017-09-20 |
2022-08-30 |
杭州英创医药科技有限公司 |
作为ido抑制剂和/或ido-hdac双重抑制剂的多环化合物
|
|
JP2020536881A
(ja)
|
2017-10-12 |
2020-12-17 |
レヴォリューション・メディスンズ，インコーポレイテッド |
アロステリックｓｈｐ２阻害剤としてのピリジン、ピラジンおよびトリアジン化合物
|
|
KR102705509B1
(ko)
|
2017-10-24 |
2024-09-12 |
상가모 테라퓨틱스, 인코포레이티드 |
희귀 질환의 치료를 위한 방법 및 조성물
|
|
EP3479845A1
(en)
|
2017-11-06 |
2019-05-08 |
Stalicla S.A. |
Challenge test for diagnosing subtype of autism spectrum disease
|
|
US10905707B2
(en)
|
2017-11-10 |
2021-02-02 |
University Of Massachusetts |
Compositions and methods for the treatment of expanded repeat-associated disorders
|
|
JP7399870B2
(ja)
|
2018-03-27 |
2023-12-18 |
ピーティーシー セラピューティクス， インコーポレイテッド |
ハンチントン病を処置するための化合物
|
|
WO2019199972A1
(en)
|
2018-04-10 |
2019-10-17 |
Skyhawk Therapeutics, Inc. |
Compounds for the treatment of cancer
|
|
KR20210038845A
(ko)
|
2018-06-27 |
2021-04-08 |
피티씨 테라퓨틱스, 인크. |
헌팅턴병 치료를 위한 헤테로아릴 화합물
|
|
HUE068060T2
(hu)
|
2018-06-27 |
2024-12-28 |
Ptc Therapeutics Inc |
Heterociklikus és heteroaril vegyületek Huntington-kór kezelésére
|
|
EA202190116A1
(ru)
|
2018-06-27 |
2021-08-30 |
Реборна Биосайенсиз, Инк. |
Агент для профилактики или лечения спинальной мышечной атрофии
|
|
US11685746B2
(en)
|
2018-06-27 |
2023-06-27 |
Ptc Therapeutics, Inc. |
Heteroaryl compounds for treating Huntington's disease
|
|
US11987568B2
(en)
|
2018-08-03 |
2024-05-21 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Allosteric inhibitor of WEE1 kinase
|
|
TW202028183A
(zh)
|
2018-10-10 |
2020-08-01 |
大陸商江蘇豪森藥業集團有限公司 |
含氮雜芳類衍生物調節劑、其製備方法和應用
|
|
US11129829B2
(en)
*
|
2019-06-17 |
2021-09-28 |
Skyhawk Therapeutics, Inc. |
Methods for modulating splicing
|
|
AU2021228285A1
(en)
|
2020-02-28 |
2022-09-29 |
Remix Therapeutics Inc. |
Compounds and methods for modulating splicing
|
|
EP4110775A1
(en)
|
2020-02-28 |
2023-01-04 |
Remix Therapeutics Inc. |
Thiophenyl derivatives useful for modulating nucleic acid splicing
|
|
IL295953A
(en)
|
2020-02-28 |
2022-10-01 |
Remix Therapeutics Inc |
Pyridazine derivatives regulate nucleic acid splicing
|
|
CN115515679A
(zh)
|
2020-02-28 |
2022-12-23 |
雷密克斯医疗公司 |
杂环酰胺及其用于调节剪接的用途
|
|
BR112022020423A2
(pt)
|
2020-04-08 |
2022-11-29 |
Remix Therapeutics Inc |
Compostos e métodos para modulação de splicing
|
|
CN116134036A
(zh)
|
2020-04-08 |
2023-05-16 |
雷密克斯医疗公司 |
用于调节剪接的化合物和方法
|